Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos

• Autores: Rodrigo Quera, Lilian Flores, Paulina Núñez, Patricio Ibáñez
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 148, Nº. 7, 2020, págs. 1039-1043
• Idioma: español
• Títulos paralelos:
  • Tofacitinib for the treatment of ulcerative colitis. Report of two cases
• Enlaces
  • Texto completo
• Resumen

  • Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.